Saudi doctor leads a medical team at Cleveland Hospital to get approval for an autism diagnosis device by the US FDA
Washington-- Director of the Pediatric Neurosciences Center at Cleveland Clinic Hospital, Ohio, in the United States of America, a consultant pediatric neurologist, Dr. Mohammed Al-Dosari, said that it is expected to meet the requirements of the US Food and Drug Administration (FDA) by the end of 2023 to adopt an innovative method for diagnosing autism in children through an eye movement tracking device without having to rely on observations of family or specialists.
In a statement to the Saudi Press Agency (SPA), Al-Dosari said, that the center has tested the accuracy of the device in cooperation with several universities and prestigious US autism centers, as well as several centers in the Gulf region, namely the Prince Mohammed bin Salman Center for Autism and Growth Disorders in Riyadh, pointing out that the device is registered as a patent in the US for the Cleveland Clinic Innovation Center.
With this cutting-edge method, he added that autism will be diagnosed at an earlier age while also improving diagnostic accuracy, lowering costs, and maximizing competencies.
Source: Saudi Press Agency